PL2173325T3 - Preparaty cyklicznej somatostatyny o powolnym uwalnianiu - Google Patents

Preparaty cyklicznej somatostatyny o powolnym uwalnianiu

Info

Publication number
PL2173325T3
PL2173325T3 PL08762364T PL08762364T PL2173325T3 PL 2173325 T3 PL2173325 T3 PL 2173325T3 PL 08762364 T PL08762364 T PL 08762364T PL 08762364 T PL08762364 T PL 08762364T PL 2173325 T3 PL2173325 T3 PL 2173325T3
Authority
PL
Poland
Prior art keywords
slow
release formulations
cyclic somatostatin
somatostatin
cyclic
Prior art date
Application number
PL08762364T
Other languages
English (en)
Inventor
Markus Johnsson
Fredrik Joabsson
Catalin Nistor
Krister Thuresson
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PL2173325T3 publication Critical patent/PL2173325T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL08762364T 2007-06-15 2008-06-13 Preparaty cyklicznej somatostatyny o powolnym uwalnianiu PL2173325T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0711656.9A GB0711656D0 (en) 2007-06-15 2007-06-15 Formulations

Publications (1)

Publication Number Publication Date
PL2173325T3 true PL2173325T3 (pl) 2017-02-28

Family

ID=38332211

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08762364T PL2173325T3 (pl) 2007-06-15 2008-06-13 Preparaty cyklicznej somatostatyny o powolnym uwalnianiu

Country Status (19)

Country Link
US (4) US9974861B2 (pl)
EP (2) EP2173325B1 (pl)
JP (1) JP5557738B2 (pl)
KR (2) KR20140049090A (pl)
CN (1) CN101842082B (pl)
AU (1) AU2008263641A1 (pl)
CA (2) CA2690715C (pl)
CY (1) CY1118245T1 (pl)
DK (1) DK2173325T3 (pl)
ES (1) ES2604205T3 (pl)
GB (1) GB0711656D0 (pl)
HK (1) HK1222333A1 (pl)
HR (1) HRP20161500T1 (pl)
HU (1) HUE030943T2 (pl)
LT (1) LT2173325T (pl)
PL (1) PL2173325T3 (pl)
PT (1) PT2173325T (pl)
SI (1) SI2173325T1 (pl)
WO (1) WO2008152401A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
DK1845942T3 (da) 2005-01-14 2014-04-28 Camurus Ab GNRH-analogformuleringer
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
WO2006077362A1 (en) 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
CN105456206B (zh) 2010-01-13 2018-12-14 益普生制药股份有限公司 用于延缓释放生长抑素类似物的药物组合物的制备方法
CA2836847C (en) * 2011-05-25 2021-06-29 Camurus Ab Controlled release peptide formulations
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
JP6081480B2 (ja) 2011-12-05 2017-02-15 カムルス エービー 頑強な徐放性製剤
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EA035495B1 (ru) * 2012-05-25 2020-06-25 Камурус Аб Состав-предшественник, содержащий агонист рецепторов соматостатина, способ лечения путем его введения, его применение, предварительно заполненное устройство, содержащее его, и набор, содержащий указанное устройство
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
JP6869720B2 (ja) * 2013-06-13 2021-05-12 アンチセンス セラピューティクス リミテッド 併用療法
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
SG10201803370XA (en) 2013-10-22 2018-06-28 Prolynx Llc Conjugates of somatostatin and its analogs
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
UY37969A (es) * 2017-11-15 2019-06-28 Rhythm Pharmaceuticals Inc Formulaciones de peptidos de liberación sostenida
US20220088150A1 (en) * 2018-09-20 2022-03-24 Biovena Science, Llc Octreotide Microsphere-Based Arterial Embolization for Treating Obesity
EP3856262A1 (en) * 2018-09-25 2021-08-04 Advanced Accelerator Applications (Italy) Srl Combination therapy
WO2020240017A1 (en) 2019-05-29 2020-12-03 Camurus Ab Lipid-controlled release compositions
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845204A (en) * 1973-05-22 1974-10-29 American Home Prod Somatostatin as inhibiting agent in prolactin release
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) * 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
CA2535463A1 (en) * 1989-07-07 1991-01-08 Novartis Ag Octreotide-pamoate and its use in sustained release formulations of water soluble peptides
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US5531925A (en) 1991-10-04 1996-07-02 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
AU685262B2 (en) 1994-03-30 1998-01-15 Gs Development Ab Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
JPH11513393A (ja) 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO1998047487A1 (en) 1997-04-17 1998-10-29 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SI1140148T1 (sl) 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6991809B2 (en) 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
EP1663468B1 (en) 2003-08-04 2008-10-15 Camurus Ab Method for loading amphiphile particles with active agents
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
WO2005046642A1 (en) 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
JP4966018B2 (ja) 2004-01-23 2012-07-04 カムルス エービー 三元非ラメラ脂質組成物
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
ATE401054T1 (de) 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
KR101234885B1 (ko) 2004-08-04 2013-02-19 카무러스 에이비 비층상 분산을 형성하는 조성물
KR100983746B1 (ko) 2005-01-14 2010-09-24 카무러스 에이비 소마토스타틴 유사 제형
CA2594710C (en) 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
DK1845942T3 (da) 2005-01-14 2014-04-28 Camurus Ab GNRH-analogformuleringer
US8871712B2 (en) * 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
WO2006077362A1 (en) 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
US20070111930A1 (en) * 2005-11-10 2007-05-17 Palle Venkata Raghavendra A Process for preparing vapreotide
EP3058972A1 (en) 2005-11-17 2016-08-24 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
JP6081480B2 (ja) * 2011-12-05 2017-02-15 カムルス エービー 頑強な徐放性製剤

Also Published As

Publication number Publication date
KR20100023033A (ko) 2010-03-03
CA2690715A1 (en) 2008-12-18
CN101842082B (zh) 2013-12-18
PT2173325T (pt) 2016-11-30
EP2173325B1 (en) 2016-10-19
GB0711656D0 (en) 2007-07-25
KR20140049090A (ko) 2014-04-24
ES2604205T3 (es) 2017-03-03
EP2992873A1 (en) 2016-03-09
CA2939686C (en) 2019-08-27
JP5557738B2 (ja) 2014-07-23
HK1222333A1 (zh) 2017-06-30
HUE030943T2 (en) 2017-06-28
CA2690715C (en) 2016-08-23
HRP20161500T1 (hr) 2016-12-16
AU2008263641A1 (en) 2008-12-18
US9974861B2 (en) 2018-05-22
WO2008152401A1 (en) 2008-12-18
CN101842082A (zh) 2010-09-22
CY1118245T1 (el) 2017-06-28
DK2173325T3 (en) 2016-12-12
US20210268112A1 (en) 2021-09-02
US20190054177A1 (en) 2019-02-21
CA2939686A1 (en) 2008-12-18
US20100210519A1 (en) 2010-08-19
KR101483320B1 (ko) 2015-01-16
SI2173325T1 (sl) 2017-01-31
US20150366973A1 (en) 2015-12-24
JP2010529982A (ja) 2010-09-02
EP2173325A1 (en) 2010-04-14
LT2173325T (lt) 2016-11-25

Similar Documents

Publication Publication Date Title
LT2173325T (lt) Ciklinio somatostatino lėto atpalaidavimo formos
GB0716385D0 (en) Formulations
GB0815435D0 (en) Formulations
GB2459691B (en) Formulations
GB0712884D0 (en) Formulations
GB0823269D0 (en) Formulations
IL197760A0 (en) Formulations comprising cyclic compounds
ZA201102446B (en) Oral formulation
GB0711957D0 (en) Formulations
GB0821789D0 (en) Formulations
GB0809979D0 (en) Formulations
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS
EP2307021A4 (en) FORMULATIONS
IL213559A0 (en) Oral formulations
HK1217912A1 (zh) 控釋肽製劑
GB0810232D0 (en) Formulations
GB0705179D0 (en) Formulations
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
ZA200802484B (en) Anthelmintic formulations
GB0710350D0 (en) Formulations
GB0710346D0 (en) Formulations
GB0708663D0 (en) Formulations
GB0701993D0 (en) Formulations